Arca
Skip to content
Tools
Tools

ITK: Tyrosine-protein kinase ITK/TSK

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Tyrosine kinase that plays an essential role in regulation of the adaptive immune response.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who Is On It, and How Far Along

Every drug ChEMBL records acting on ITK, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Pazopanib

Phase 30

    Phase 20

      Phase 10

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionMechanismOpen trialsWarnings
        PazopanibApprovedNovartis PharmaceuticalsSmall moleculeInhibitorTyrosine-protein kinase ITK/TSK inhibitor27Boxed warning

        Open Trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainPazopanib—Active, not recruitingBristol-Myers Squibb2026-10-01
        A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasPazopanibPhase 1RecruitingM.D. Anderson Cancer Center2026-03-03
        A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaPazopanibPhase 2RecruitingImbioray (Hangzhou) Biomedicine Co., Ltd.2025-07-25
        Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)PazopanibPhase 1 / Phase 2RecruitingTianjin Medical University Second Hospital2025-03-26
        Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or AdolescentsPazopanibPhase 2RecruitingShandong Cancer Hospital and Institute2025-02-10
        Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPazopanibPhase 2RecruitingTianjin Medical University Second Hospital2024-12-18
        Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)PazopanibPhase 3RecruitingSun Yat-sen University2024-12-10
        A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)PazopanibPhase 3RecruitingIntensity Therapeutics, Inc.2024-02-16

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        Lymphoproliferative syndrome 1
        0.77
        Autosomal recessive lymphoproliferative disease
        0.62
        Hodgkins lymphoma
        0.49
        Hypothyroidism
        0.47
        Combined immunodeficiency
        0.46
        Neoplasm
        0.42
        Hereditary disease
        0.41

        Genes and Related Targets

        Complexes and families that share a gene with this target
        Genes
        ITK

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2959, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q08881, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.